Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation (MemIprov)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
DSM Nutritional Products, Inc.
ClinicalTrials.gov Identifier:
NCT01647919
First received: June 22, 2012
Last updated: August 6, 2013
Last verified: August 2013
  Purpose

The purpose of the study is to examine the efficacy of cogniVida™ on learning and memory performance (executive function, associative, spatial and verbal memory) as well as on mood and attention parameters after four, eight and eleven weeks of supplementation and in comparison with placebo.

cogniVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The investigators do not claim that this supplement is meant to treat any ailment.


Condition Intervention Phase
Healthy
Dietary Supplement: cogniVida™ 100 mg/day
Dietary Supplement: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation

Resource links provided by NLM:


Further study details as provided by DSM Nutritional Products, Inc.:

Primary Outcome Measures:
  • Associative / Visual Memory (Name to Face Recall (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Associative / Visual Memory Task on a computer. Outcome measurements: Change of accuracy and speed of response from baseline measurement to 1 month

  • Associative / Visual Memory (Name to Face Recall (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Associative / Visual Memory Task on a computer. Outcome measurements: Change of accuracy and speed of response from baseline measurement to 2 months

  • Associative / Visual Memory (Name to Face Recall (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Associative / Visual Memory Task on a computer. Outcome measurements: Change of accuracy and speed of response from baseline measurement to 3 months

  • Visual Memory (Picture Recognition (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Visual Memory Tasks on a computer: Outcome measurement: Change in percent correct from baseline measurement to 1 month

  • Visual Memory (Picture Recognition (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Visual Memory Tasks on a computer: Outcome measurement: Change in percent correct from baseline measurement to 2 months

  • Visual Memory (Picture Recognition (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Visual Memory Tasks on a computer: Outcome measurement: Change in percent correct from baseline measurement to 3 months

  • Working and Spatial Memory ('Sternberg' Numeric Working Memory task (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Working and Spatial Memory Tasks on a computer. Outcome measurements: Change of speed and accuracy of performance from baseline measurement to 1 month

  • Working and Spatial Memory ('Sternberg' Numeric Working Memory task (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Working and Spatial Memory Tasks on a computer. Outcome measurements: Change of speed and accuracy of performance from baseline measurement to 2 months

  • Working and Spatial Memory ('Sternberg' Numeric Working Memory task (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Working and Spatial Memory Tasks on a computer. Outcome measurements: Change of speed and accuracy of performance from baseline measurement to 3 months

  • Working and Spatial Memory ('Corsi Blocks'(COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Working and Spatial Memory Tasks on a computer. Outcome measurement: Change of span score from baseline measurement to 1 month

  • Working and Spatial Memory ('Corsi Blocks'(COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Working and Spatial Memory Tasks on a computer. Outcome measurement: Change of span score from baseline measurement to 2 months

  • Working and Spatial Memory ('Corsi Blocks'(COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Working and Spatial Memory Tasks on a computer. Outcome measurement: Change of span score from baseline measurement to 3 months

  • Executive Function and Verbal Memory (Peg and Ball Task (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Executive Function and Verbal Memory Tasks on a computer. Outcome measurements: Change of accuracy, thinking time and speed of performance from baseline measurement to 1 month

  • Executive Function and Verbal Memory (Peg and Ball Task (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Executive Function and Verbal Memory Tasks on a computer. Outcome measurements: Change of accuracy, thinking time and speed of performance from baseline measurement to 2 months

  • Executive Function and Verbal Memory (Peg and Ball Task (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Executive Function and Verbal Memory Tasks on a computer. Outcome measurements: Change of accuracy, thinking time and speed of performance from baseline measurement to 3 months

  • Executive Function and Verbal Memory (Delayed Word Recognition (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Executive Function and Verbal Memory Tasks on a computer. Outcome measurements: Change of accuracy and speed of response from baseline measurement to 1 month

  • Executive Function and Verbal Memory (Delayed Word Recognition (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Executive Function and Verbal Memory Tasks on a computer. Outcome measurements: Change of accuracy and speed of response from baseline measurement to 2 months

  • Executive Function and Verbal Memory (Delayed Word Recognition (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Executive Function and Verbal Memory Tasks on a computer. Outcome measurements: Change of accuracy and speed of response from baseline measurement to 3 months


Secondary Outcome Measures:
  • Attention and Concentration (Choice Reaction Time (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]

    Attention and Concentration Tasks on a computer. Outcome measurement:

    Change of speed of response from baseline to 1 month.


  • Attention and Concentration (Choice Reaction Time (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]

    Attention and Concentration Tasks on a computer. Outcome measurement:

    Change of speed of response from baseline to 2 months.


  • Attention and Concentration (Choice Reaction Time (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]

    Attention and Concentration Tasks on a computer. Outcome measurement:

    Change of speed of response from baseline to 3 months.


  • Attention and Concentration (Rapid Visual Information Processing (COMPASS)) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]

    Attention and Concentration Tasks on a computer. Outcome measurement:

    Change of accuracy, false alarms, speed of response from baseline to 1 month.


  • Attention and Concentration (Rapid Visual Information Processing (COMPASS)) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]

    Attention and Concentration Tasks on a computer. Outcome measurement:

    Change of accuracy, false alarms, speed of response from baseline to 2 months.


  • Attention and Concentration (Rapid Visual Information Processing (COMPASS)) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]

    Attention and Concentration Tasks on a computer. Outcome measurement:

    Change of accuracy, false alarms, speed of response from baseline to 3 months.


  • Bond-Lader Visual Analog Scales (VAS) of Mood [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    This questionnaire of 16 analogue scales derives three factors that assess change in self-rated alertness, self-rated calmness and self-rated contentment. (presented within COMPASS) Outcome measurement: Change of these parameters from baseline to 1 month.

  • Bond-Lader Visual Analog Scales (VAS) of Mood [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    This questionnaire of 16 analogue scales derives three factors that assess change in self-rated alertness, self-rated calmness and self-rated contentment. (presented within COMPASS) Outcome measurement: Change of these parameters from baseline to 2 months.

  • Bond-Lader Visual Analog Scales (VAS) of Mood [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    This questionnaire of 16 analogue scales derives three factors that assess change in self-rated alertness, self-rated calmness and self-rated contentment. (presented within COMPASS) Outcome measurement: Change of these parameters from baseline to 3 months.

  • Profile of Mood States (POMS) Questionnaire [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]

    The POMS provides scales of tension-anxiety, depression-dejection, anger

    -hostility, vigor-activity, fatigue-inertia and confusion-bewilderment. A score will be obtained from each and a single score of "mood disturbance" will be computed. (paper and pencil) Outcome measurement: Change of these parameters from baseline to 1 month.


  • Profile of Mood States (POMS) Questionnaire [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]

    The POMS provides scales of tension-anxiety, depression-dejection, anger

    -hostility, vigor-activity, fatigue-inertia and confusion-bewilderment. A score will be obtained from each and a single score of "mood disturbance" will be computed. (paper and pencil) Outcome measurement: Change of these parameters from baseline to 2 months.


  • Profile of Mood States (POMS) Questionnaire [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]

    The POMS provides scales of tension-anxiety, depression-dejection, anger

    -hostility, vigor-activity, fatigue-inertia and confusion-bewilderment. A score will be obtained from each and a single score of "mood disturbance" will be computed. (paper and pencil) Outcome measurement: Change of these parameters from baseline to 3 months.


  • Prospective and Retrospective Memory Questionnaire (PRMQ) [ Time Frame: Day 0 (baseline) to day 28 ] [ Designated as safety issue: No ]
    Subjects will be asked about their subjective 'prospective' and 'retrospective' memory performance - paper and pencil Outcome measurement: Change of memory scores from baseline to 1 month.

  • Prospective and Retrospective Memory Questionnaire (PRMQ) [ Time Frame: Day 0 (baseline) to day 56 ] [ Designated as safety issue: No ]
    Subjects will be asked about their subjective 'prospective' and 'retrospective' memory performance - paper and pencil Outcome measurement: Change of memory scores from baseline to 2 months.

  • Prospective and Retrospective Memory Questionnaire (PRMQ) [ Time Frame: Day 0 (baseline) to day 77 ] [ Designated as safety issue: No ]
    Subjects will be asked about their subjective 'prospective' and 'retrospective' memory performance - paper and pencil Outcome measurement: Change of memory scores from baseline to 3 months.


Enrollment: 88
Study Start Date: May 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: cogniVida™ 100 mg/day Dietary Supplement: cogniVida™ 100 mg/day
4 capsules 25 mg (total 100 mg) cogniVida™ once a day
Placebo Comparator: Placebo Dietary Supplement: Placebo
4 capsules of placebo identical to cogniVida™ once a day

  Eligibility

Ages Eligible for Study:   50 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males or Females, age 50 - 65 years
  • Subject agrees to maintain his or her habitual diet and physical activity patterns throughout the study period.
  • Subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine laboratory test results.
  • Subject has a body mass index (BMI) of ≥18.5 and ≤ 30.00 kg/m2 at screening.
  • Subject is willing to refrain from consuming alcoholic drinks 24 h prior to test days and until the end of each assessment period and refrain from consuming caffeine, and caffeine-containing products 12 h prior to test days and until the end of each assessment period.
  • Subject is willing to refrain from vigorous physical activity 12 h prior to test days.
  • Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion Criteria:

  • Subject has a positive drug screening of amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, 3,4-methylenedioxymethamphetamine, opiates or tricyclic antidepressants at screening or at any of the admission days.
  • Subjects has a positive breath alcohol and breath carbon monoxide test at screening or at any of the admission days.
  • Subject has abnormal clinical chemistry and hematology laboratory test results of clinical significance according to established criteria.
  • Subjects with a history of renal or hepatic disease that is likely to interfere with the metabolism or excretion of the test product.
  • Subject has donated more than 300 mL of blood during the three months prior to screening.
  • Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg) as defined by the average blood pressure measured at screening.
  • Subject has a history, in the judgment of the Investigator, of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
  • Excessive habitual caffeine consumption (>500 mg caffeine/d), following screening and throughout the study period. Caffeine consumption will be assessed using the Caffeine Consumption Questionnaire
  • Subjects who are on a significant hypocaloric diet (i.e. < 1200 calories per day) aiming for significant weight loss.
  • Use of any sleep aid medication within four days prior to each test day (visits 2, 3, 4, 5; days 0, 28, 56, 77).
  • Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
  • Subject is pregnant, planning to be pregnant during the study period, lactating, or women who consider themselves to be of childbearing potential and who are engaged in an active sex life who are unwilling to commit to the use of an approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation.
  • Use of any psychotropic medication within four weeks of visit 1, day -14 and throughout the study.
  • Use of dietary supplements containing any of the following: lutein, ginkgo biloba, St. John's wort, ginseng, gotu kola (Indian pennywort); daily doses of vitamin E (≥30 mg/d) or folic acid (≥400 ug/d); thiamine, riboflavin, and/or pyridoxine (≥2 mg/d); and eicosapentaenoic acid (EPA), docosahexaenoic acid or a combination of EPA + DHA (≥500 mg/d) within 2 weeks prior to screening.
  • Subject has had exposure to any non-registered drug product within 30 days prior to the screening visit and throughout the study.
  • Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >60g (men) / 40g (women) pure alcohol per day (7 / 5.5 units).
  • Subject has a known allergy or sensitivity to study product or any ingredients of the study product or meals provided.
  • The subject is unable to perform the tests on the COMPASS System during training to the established acceptable levels for participation in this type of study.
  • Use of stevia extract sweetened products/drinks or stevia leaves within 1 month of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01647919

Locations
United Kingdom
Northumbria University
Newcastle upon Tyne, United Kingdom, NE1 8ST
Sponsors and Collaborators
DSM Nutritional Products, Inc.
Investigators
Principal Investigator: David Kennedy, Prof Director of the 'Brain, Performance and Nutrition Research Centre', Northumbria University, UK
Principal Investigator: Crystal Haskell, PhD Associate Director of the 'Brain, Performance and Nutrition Research Centre', Northumbria University, UK
  More Information

No publications provided

Responsible Party: DSM Nutritional Products, Inc.
ClinicalTrials.gov Identifier: NCT01647919     History of Changes
Other Study ID Numbers: 2012-01-10-STEV
Study First Received: June 22, 2012
Last Updated: August 6, 2013
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by DSM Nutritional Products, Inc.:
Cognition
Attention
Memory
Mood

ClinicalTrials.gov processed this record on September 18, 2014